CARVYKTI® is Legend Biotech’s first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with relapsed or refractory multiple myeloma following a one-time treatment with ciltacabtagene autoleucel SOMERSET, N.J.— (BUSINESS WIRE)—May 26, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend […]
LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen.Piscataway, NJ (May 30, 2018) – Legend Biotech, a subsidiary of GenScript Biotech Corporation (HKEx: 1548), announced today that the U.S. Food and Drug Administration (FDA) has authorized its development partner, Janssen Biotech, Inc. (“Janssen”), to commence a Phase 1b/2 […]
U.S. FDA approval of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) SOMERSET, N.J.— (BUSINESS WIRE)—May 18, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that eight company-sponsored abstracts were accepted at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the […]
SOMERSET, N.J.— (BUSINESS WIRE)—May 9, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the promotion of Lori Macomber, CPA, to Chief Financial Officer (CFO), effective immediately. Ms. Macomber assumes the role from Dr. Ying Huang, who has been both CFO […]
SOMERSET, N.J.—May 6, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Bank of America Securities 2022 Healthcare ConferencePresentation Date & Time: Wednesday, May 11, 2022 at 5:20pm PT / 8:20pm ETLocation: Las […]
Piscataway, NJ (November 14, 2018): China Healthcare Summit 2018 hosted by BioCentury and BayHelix announced Dr. Frank Zhang, GenScript’s founder, as the winner of its Person of the Year Award. The goal of this award was to recognize an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem of drug and/or medical technology R&D, […]
28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meeting Overall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reached Results from Cohorts A and B of the […]
SOMERSET, N.J.—(BUSINESS WIRE)—June 3, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate LB1908 in a Phase 1 clinical trial in the United […]
SOMERSET, N.J. — (BUSINESS WIRE) —June 1, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today reported its first quarter 2022 unaudited financial results. “The year began with an exciting start as we received the company’s first-ever U.S. FDA approval for […]
SOMERSET, N.J.— (BUSINESS WIRE)—August 4, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced the appointment of three new directors to its Board: Mr. Tomas Heyman as Class I director of Legend Biotech, Dr. Fangliang “Frank” Zhang as Class II director […]
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.